Key Points
- Jonathan Allan, Stoke's General Counsel, sold 4,267 shares on March 17 at an average of $33.01 and an additional 4,628 shares on March 18 at $31.34, reducing his stake by about 11.31% to 33,464 shares (valued at roughly $1.10M); the trades were disclosed on an SEC Form 4.
- Multiple insiders (including the CFO and GC) disclosed sizable sales March 17–19, which could pressure sentiment, even as analysts remain largely bullish—MarketBeat shows a consensus "Moderate Buy" with an average price target of about $39.83, and STOK trading near $33 with a $2.01B market cap.
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 1,461 shares of Stoke Therapeutics stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $29.99, for a total transaction of $43,815.39. Following the completion of the transaction, the insider directly owned 40,702 shares in the company, valued at approximately $1,220,652.98. The trade was a 3.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Barry Ticho also recently made the following trade(s):
- On Wednesday, March 18th, Barry Ticho sold 6,686 shares of Stoke Therapeutics stock. The shares were sold at an average price of $31.34, for a total transaction of $209,539.24.
- On Tuesday, March 17th, Barry Ticho sold 6,164 shares of Stoke Therapeutics stock. The shares were sold at an average price of $33.01, for a total transaction of $203,473.64.
Stoke Therapeutics Trading Up 3.7%
NASDAQ STOK opened at $34.41 on Friday. The firm's fifty day simple moving average is $32.60 and its two-hundred day simple moving average is $29.93. The firm has a market capitalization of $2.04 billion, a P/E ratio of 51.46 and a beta of 1.07. Stoke Therapeutics, Inc. has a 12-month low of $5.35 and a 12-month high of $40.22.
Analysts Set New Price Targets
A number of equities research analysts have commented on the company. Chardan Capital reiterated a "buy" rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. Guggenheim assumed coverage on Stoke Therapeutics in a research note on Thursday, February 5th. They set a "buy" rating and a $60.00 price target on the stock. Weiss Ratings restated a "hold (c-)" rating on shares of Stoke Therapeutics in a report on Monday, December 29th. Loop Capital set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Monday, January 5th. Finally, HC Wainwright lifted their target price on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the stock a "buy" rating in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $39.83.
Read Our Latest Report on Stoke Therapeutics
Institutional Trading of Stoke Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC purchased a new stake in Stoke Therapeutics during the 4th quarter valued at about $26,000. Harbour Investments Inc. raised its stake in shares of Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company's stock worth $38,000 after purchasing an additional 898 shares during the last quarter. Generali Investments Management Co LLC acquired a new stake in shares of Stoke Therapeutics during the third quarter worth about $41,000. BNP Paribas Financial Markets lifted its holdings in shares of Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock worth $48,000 after purchasing an additional 1,668 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company's stock valued at $50,000 after buying an additional 3,591 shares during the last quarter.
Key Stoke Therapeutics News
Here are the key news stories impacting Stoke Therapeutics this week:
Stoke Therapeutics Company Profile
(
Get Free Report)
Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.
The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
